Atara to raise $175M in secondary public offering
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Atara immunotherapy for mesothelioma promising
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Stellar Biotechnologies revenues fall in third quarter
Revenues for Port Hueneme-based immunotherapy developer Stellar Biotechnologies fell to $20,000 for its fiscal third quarter, about a ninth what it was for the same quarter the prior year. The slump in sales was a product of lower volume orders for the three months ended June 30, the company said in an earnings release Aug. Read More →
SerImmune gets $8 million in financing from Illumina Ventures
Santa Barbara immunotherapy and diagnostic company SerImmune received $8 million in financing from San Francisco-based Illumina Ventures to expand its immune mapping platform and database. Illumina invests primarily in early-stage companies researching genomics, life science and health care. A subsidiary of pharmaceutical giant Merck also participated in the financing round, alongside other undisclosed investors. Mapping Read More →
Stellar Biotechnologies reports $1.1 million loss for quarter
Stellar Biotechnologies, based in Port Hueneme, reported drops in both revenues and expenses for the quarter ended March 31. Revenues decreased 81 percent from $330,000 during the same quarter the previous year to $60,000 for the most recent quarter. The immunotherapy developer and manufacturer attributed the decrease to lower sales volume for pre-clinical studies, compared Read More →
Stellar Biotechnologies gets immunotherapy manufacturing contract
Port Hueneme immunotherapy company Stellar Biotechnologies announced an exclusive multi-year supply agreement with Taiwanese manufacturer Amaran Biotechnology. The agreement coincides with late-stage clinical studies for an immunotherapy called Adagloxad Simolenin, which treats cancers including metastatic breast cancer. The two companies will also develop the manufacturing process for Stellar’s Keyhole Limpet Hemocyanin conjugated vaccine, made from Read More →
Stellar Biotechnologies revenues up but losses grow
Stellar Biotechnologies’ revenues increased slightly during the third quarter of 2016 but losses widened as the company signed a new partnership with a French company and held an offering for institutional investors, the company said in a quarterly earnings report Aug. 8. Stellar revenues increased slightly from $157,748 during the third quarter of 2015 to Read More →
